The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Zometa zoledronic acid | Phoenix Labs Unlimited Company | Cancer; Fractures, Bone | 🇪🇺 EU 2001-03-20 | Order → |
| Kaletra lopinavir;ritonavir | AbbVie Deutschland GmbH & Co. KG | HIV Infections | 🇪🇺 EU 2001-03-19 | Order → |
| Vaniqa eflornithine | Almirall, S.A. | Hirsutism | 🇪🇺 EU 2001-03-19 | Order → |
| Rapamune sirolimus | Pfizer Europe MA EEIG | Graft Rejection; Kidney Transplantation | 🇪🇺 EU 2001-03-13 | Order → |
| Fasturtec rasburicase | Sanofi Winthrop Industrie | Hyperuricemia | 🇪🇺 EU 2001-02-23 | Order → |
| Metalyse tenecteplase | Boehringer Ingelheim International GmbH | Myocardial Infarction | 🇪🇺 EU 2001-02-23 | Order → |
| Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG tenecteplase | Boehringer Ingelheim International GmbH | Myocardial Infarction | 🇪🇺 EU 2001-02-23 | Order → |
| NutropinAq somatropin | Ipsen Pharma | Turner Syndrome; Dwarfism, Pituitary | 🇪🇺 EU 2001-02-15 | Order → |
| Ovitrelle choriogonadotropin alfa | Merck Europe B.V. | Anovulation; Reproductive Techniques, Assisted; Infertility, Female | 🇪🇺 EU 2001-02-02 | Order → |
| Prevenar pneumococcal saccharide conjugated vaccine, adsorbed | Pfizer Limited | Pneumococcal Infections; Immunization | 🇪🇺 EU 2001-02-02 | Order → |
| Xeloda capecitabine | CHEPLAPHARM Arzneimittel GmbH | Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms | 🇪🇺 EU 2001-02-02 | Order → |
| Prandin repaglinide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2001-01-29 | Order → |
| NeuroBloc botulinum toxin type B | Sloan Pharma S.a.r.l | Torticollis | 🇪🇺 EU 2001-01-22 | Order → |
| Aerius desloratadine | Organon N.V. | Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal | 🇪🇺 EU 2001-01-15 | Order → |
| Allex desloratadine | Schering-Plough Europe | Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal | 🇪🇺 EU 2001-01-15 | Order → |
| Azomyr desloratadine | Organon N.V. | Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal | 🇪🇺 EU 2001-01-15 | Order → |
| Neoclarityn desloratadine | Organon N.V. | Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal | 🇪🇺 EU 2001-01-15 | Order → |
| Opulis desloratadine | Schering-Plough Europe | Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal | 🇪🇺 EU 2001-01-15 | Order → |
| Trizivir abacavir;lamivudine;zidovudine | ViiV Healthcare BV | HIV Infections | 🇪🇺 EU 2000-12-27 | Order → |
| Luveris lutropin alfa | Merck Europe B.V. | Ovulation Induction; Infertility, Female | 🇪🇺 EU 2000-11-29 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.